Pancreatic Cancer, Solid Tumor, Adult
Conditions
Brief summary
This is a single center, open-label, phase 1 study to evaluate the safety and efficacy of U87 CART in treating advanced solid tumor .
Detailed description
Following consent, patients must have tumor tissue evaluated by IHC assay. Patients meeting all eligibility criteria will undergo a leukapheresis procedure to collect autologous mononuclear cells for manufacture of investigational drug product (U87). Following manufacture of the drug product, subjects will receive preconditioning prior to U87 infusion. All subjects will be asked to continue to undergo long-term gene safety follow-up.
Interventions
DRUGU87 CAR-T
Subjects will be pretreated with cyclophosphamide 250\ 500 mg/m2( body surface area) for 3 days prior to Intravenous injection of U87, followed by intraartery of U87 14 days later with intravenous IL-2. Researchers can perform intratumoral injection based on their judgment.This study will explore two dose of dose 1 (DL-1): 1×106 (±20%) to dose 2 (DL-2): 1×107 (±20%),each group was enrolled in 3\ 6 patients.
Sponsors
Shanghai 10th People's Hospital
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Voluntary informed consent is given; 2. Age 18 to 75; 3. Patients with pathologically confirmed advanced solid tumor who have failed first-line therapy; or patients who are intolerant to first-line standard therapy and voluntarily give up standard therapy; 4. Immunohistochemical (IHC) staining of tumor tissue samples from patients was positive for U87 specific antigen (≥ 2 +, and the expression rate was ≥ 20%); 5. Expected survival ≥12 weeks; 6. Measurable tumor lesions according to RECIST 1.1; 7. ECOG performance score 0-1; 8. Sufficient venous access for mononuclear cell collection; 9. HBc Ab positive, HBsAg negative can be included in the group when the PCR detection of HBV DNA is negative; 10. Patients should maintain adequate organ function; 11. Dyspnea (CTCAE v5.0) ≤ Grade 1; Blood oxygen saturation\>91% without oxygen inhalation; 12. Pregnancy test was negative in women of childbearing age; Both male and female subjects should agree to use effective contraceptives during the treatment period and within the following year;
Exclusion criteria
1. Pregnant or lactating women; 2. Uncontrolled active infections; 3. Active Syphilis, HIV, hepatitis B or hepatitis C infection; 4. Congenital immunodeficiency; 5. Have serious allergic reaction to any drug to be used in this study; 6. Other incurable malignant tumors in the past three years; 7. History or presence of clinically relevant CNS pathology such as epilepsy, Cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any CNS-related autoimmune disease; 8. Have undergone cardiac angioplasty or stent implantation within 12 months, or have a history of myocardial infarction, unstable angina or other clinically significant heart diseases; 9. Subjects requiring anticoagulation or long-term antiplatelet therapy; 10. Subjects who have undergone major surgery or significant trauma within four weeks before enrolled in the study. 11. Other situations that the investigator thinks are not suitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Adverse events after U87 CAR-T cells infusion [Safety and Tolerability] | 28 days post administration of CAR-T-cells | Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0) Dose-limiting toxicity after U87 CAR-T cells infusion. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Disease control rate (DCR) of U87 CAR-T cells treatment in advanced solid tumor. [Effectiveness] | 2 years post CAR T cell infusion | Disease control rate: including CR, PR and SD(Assessed based on RECIST 1.1 criteria) |
| Objective response rate (ORR) of U87 CAR-T cells treatment in advanced solid tumor. [Effectiveness] | 2 years post CAR T cell infusion | Objective response rate includes：CR、PR(Assessed based on RECIST1.1 criteria) |
| Duration of Response (DOR) of U87 CAR-T cells treatment in advanced solid tumot[Effectiveness] | 2 years post CAR T cell infusion | DOR will be assessed from the first assessment of CR/PR/SD to the first assessment of recurrence or progression of the disease or death from any cause |
| Pharmacokinetics of U87 CAR-T cells | 2 years post CAR T cell infusion | Peak value of eripheral blood (Cmax) |
| Overall survival(OS) of U87 CAR-T cells treatment in advanced solid tumor [Effectiveness] | 2 years post CAR T cell infusion | OS will be assessed from the first U87 CAR-T cells infusion to death from any cause (Assessed based on RECIST 1.1 criteria) |
| Pharmacodynamics of U87 CAR-T cells | 2 years post CAR T cell infusion | Concentration levels of CAR-T-related serum cytokines such as IL-6, IFN γ, IL-2, TNFα, ferritin and CRP at each time point |
| Progress-free survival(PFS) of U87 CAR-T cells treatment in advanced solid tumor[Effectiveness] | 2 years post CAR T cell infusion | PFS will be assessed from the first U87 CAR-T cells infusion to death from any cause or the first assessment of progression(Assessed based on RECIST1.1 ） criteria) |
Countries
China
Contacts
Primary ContactMaoquan Li, doctor
Backup ContactShilong Han, doctor
Outcome results
None listed